Next Article in Journal
Efficacy of Lytic Phage Cocktails on Staphylococcus aureus and Pseudomonas aeruginosa in Mixed-Species Planktonic Cultures and Biofilms
Next Article in Special Issue
Are We Ready for NGS HIV Drug Resistance Testing? The Second “Winnipeg Consensus” Symposium
Previous Article in Journal
Administration of Defective Virus Inhibits Dengue Transmission into Mosquitoes
Previous Article in Special Issue
External Quality Assessment for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Unique Requirements and Challenges
Open AccessOpinion

External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations

1
National HIV and Retrovirology Laboratories at JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
2
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada
3
Data First Consulting Inc., Sebastopol, CA 95472, USA
4
Duke Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
5
Department of Molecular Pathogens and Immunity, Rush University, Chicago, IL 60612, USA
6
Division of Infectious Diseases, Brown University Alpert Medical School, Providence, RI 02906, USA
*
Author to whom correspondence should be addressed.
Viruses 2020, 12(5), 556; https://doi.org/10.3390/v12050556
Received: 20 April 2020 / Revised: 13 May 2020 / Accepted: 14 May 2020 / Published: 18 May 2020
(This article belongs to the Special Issue Next Generation Sequencing for HIV Drug Resistance Testing)
Next-generation sequencing (NGS) is likely to become the new standard method for HIV drug resistance (HIVDR) genotyping. Despite the significant advances in the development of wet-lab protocols and bioinformatic data processing pipelines, one often-missing critical component of an NGS HIVDR assay for clinical use is external quality assessment (EQA). EQA is essential for ensuring assay consistency and laboratory competency in performing routine biomedical assays, and the rollout of NGS HIVDR tests in clinical practice will require an EQA. In September 2019, the 2nd International Symposium on NGS HIVDR was held in Winnipeg, Canada. It convened a multidisciplinary panel of experts, including research scientists, clinicians, bioinformaticians, laboratory biologists, biostatisticians, and EQA experts. A themed discussion was conducted on EQA strategies towards such assays during the symposium. This article describes the logistical challenges identified and summarizes the opinions and recommendations derived from these discussions, which may inform the development of an inaugural EQA program for NGS HIVDR in the near future. View Full-Text
Keywords: HIV; drug resistance; next generation sequencing; external quality assessment HIV; drug resistance; next generation sequencing; external quality assessment
Show Figures

Figure 1

MDPI and ACS Style

Ji, H.; Parkin, N.; Gao, F.; Denny, T.; Jennings, C.; Sandstrom, P.; Kantor, R. External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations. Viruses 2020, 12, 556.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop